AHA comments on ensuring legitimate access to controlled substances

The AHA today responded to a Department of Health and Human Services request for input from health care providers and other stakeholders on ensuring legitimate access to controlled substances, including opioids, while preventing diversion and abuse. The Ensuring Patient Access and Effective Drug Enforcement Act of 2016 calls for HHS’ Office of the Assistant Secretary for Planning and Evaluation to submit a report to Congress on the issue. Among other actions, AHA recommends providing additional support for medical education, training and guidance for non-opioid pain management as well as for state drug courts, which offer justice-involved individuals with substance use disorders the opportunity to enter treatment programs.
Related News Articles
Headline
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,…
Chairperson's File
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The Senate Health, Education, Labor and Pensions Committee yesterday voted 12-11 along party lines to recommend the confirmation of Brian Christine, M.D., to…
Chairperson's File
This month Congress enacted the One Big Beautiful Bill Act — a sweeping package that contained many of President Trump’s legislative priorities on taxes,…
Headline
The Centers for Medicare & Medicaid Services July 15 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…